OBJECTIVE AND METHODS: We performed a single center analysis of 60 adult patients (33 males and 27 females) with myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia (AML) who underwent allogeneic hematopoietic stem cell transplantation (HCT) at our institution. RESULTS: Allogeneic stem cell in patients were transplanted between 1988 and 2010, 28 had an human leukocyte antigen (HLA)-identical sibling donor, 23 had an HLA-identical unrelated donor, and 9 had an 1 allele mismatched donor. The median age at time of HCT was 44 (range: 18-68) years. Conditioning therapy was myeloablative in 36 patients and consisted of a reduced-intensity conditioning (RIC) regimen in 24 patients. Graft-versus-host disease (GvHD) prophylaxis was performed with a combination of methotrexate and cyclosporine A in 36 patients, and cyclosporine A plus mycophenolate mofetil in 24 patients. The 10-year probability of overall survival was 46 %. CONCLUSION: In a multivariate analysis, we identified pretransplantation serum ferritin as the only independent adverse prognostic variable predicting survival in our patients.
OBJECTIVE AND METHODS: We performed a single center analysis of 60 adult patients (33 males and 27 females) with myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia (AML) who underwent allogeneic hematopoietic stem cell transplantation (HCT) at our institution. RESULTS: Allogeneic stem cell in patients were transplanted between 1988 and 2010, 28 had an human leukocyte antigen (HLA)-identical sibling donor, 23 had an HLA-identical unrelated donor, and 9 had an 1 allele mismatched donor. The median age at time of HCT was 44 (range: 18-68) years. Conditioning therapy was myeloablative in 36 patients and consisted of a reduced-intensity conditioning (RIC) regimen in 24 patients. Graft-versus-host disease (GvHD) prophylaxis was performed with a combination of methotrexate and cyclosporine A in 36 patients, and cyclosporine A plus mycophenolate mofetil in 24 patients. The 10-year probability of overall survival was 46 %. CONCLUSION: In a multivariate analysis, we identified pretransplantation serum ferritin as the only independent adverse prognostic variable predicting survival in our patients.
Authors: E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner Journal: N Engl J Med Date: 1975-04-17 Impact factor: 91.245
Authors: A Shimoni; I Hardan; N Shem-Tov; M Yeshurun; R Yerushalmi; A Avigdor; I Ben-Bassat; A Nagler Journal: Leukemia Date: 2006-02 Impact factor: 11.528
Authors: V Runde; T de Witte; R Arnold; A Gratwohl; J Hermans; A van Biezen; D Niederwieser; M Labopin; M P Walter-Noel; A Bacigalupo; N Jacobsen; P Ljungman; E Carreras; H J Kolb; C Aul; J Apperley Journal: Bone Marrow Transplant Date: 1998-02 Impact factor: 5.483
Authors: J-H Lee; J-H Lee; S-N Lim; D-Y Kim; S H Kim; Y-S Lee; Y-A Kang; S-I Kang; M J Jeon; M Seol; E-J Seo; H S Chi; C J Park; S Jang; S-C Yun; K-H Lee Journal: Bone Marrow Transplant Date: 2009-08-10 Impact factor: 5.483
Authors: Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz Journal: Blood Date: 2004-03-23 Impact factor: 22.113
Authors: R Martino; A Henseler; M van Lint; N Schaap; J Finke; D Beelen; S Vigouroux; E P Alessandrino; G J Mufti; J H Veelken; B Bruno; I Yakoub-Agha; L Volin; J Maertens; R Or; V Leblond; M Rovira; P Kalhs; A F Alvarez; A Vitek; J Sierra; E Wagner; M Robin; T de Witte; N Kröger Journal: Bone Marrow Transplant Date: 2017-03-20 Impact factor: 5.483